Uvax Bio LLC
Uvax Bio is a vaccine company founded in 2018, originating from Scripps Research, focusing on developing prophylactic vaccines for challenging infectious diseases using proprietary platform technology. Their mission is to solve global infectious disease threats through rational antigen design and protein engineering, aiming to become a leader in the vaccine industry and address unmet public health needs.
Industries
Nr. of Employees
small (1-50)
Products
Recombinant protein nanoparticle vaccine candidates for HIV-1
Protein nanoparticle vaccine candidates designed to present stabilized envelope trimers to elicit neutralizing antibody responses; advanced into Phase I clinical testing with interim safety and immunogenicity results reported.
Pipeline vaccine programs for multiple pathogens (preclinical and development stage)
Vaccine programs in development employing protein nanoparticle display and antigen engineering against pathogens including hepatitis C virus, RSV, hMPV, influenza, parainfluenza, Zika, dengue, Lassa, Ebola, Marburg, tuberculosis, and malaria.
Recombinant protein nanoparticle vaccine candidates for HIV-1
Protein nanoparticle vaccine candidates designed to present stabilized envelope trimers to elicit neutralizing antibody responses; advanced into Phase I clinical testing with interim safety and immunogenicity results reported.
Pipeline vaccine programs for multiple pathogens (preclinical and development stage)
Vaccine programs in development employing protein nanoparticle display and antigen engineering against pathogens including hepatitis C virus, RSV, hMPV, influenza, parainfluenza, Zika, dengue, Lassa, Ebola, Marburg, tuberculosis, and malaria.
Services
Vaccine R&D using protein nanoparticle platforms
Design and preclinical development of recombinant protein nanoparticle vaccine candidates using structure-based antigen engineering and multivalent nanoparticle display.
Process development and manufacturing scale-up
Developing research cell banks and streamlined expression and purification processes to enable production of complex protein nanoparticle vaccines at scales suitable for clinical studies.
Clinical development and trial execution
Management and conduct of early-phase clinical trials including regulatory submissions, site partnerships, participant dosing, safety monitoring, and immunogenicity assessments.
Vaccine R&D using protein nanoparticle platforms
Design and preclinical development of recombinant protein nanoparticle vaccine candidates using structure-based antigen engineering and multivalent nanoparticle display.
Process development and manufacturing scale-up
Developing research cell banks and streamlined expression and purification processes to enable production of complex protein nanoparticle vaccines at scales suitable for clinical studies.
Clinical development and trial execution
Management and conduct of early-phase clinical trials including regulatory submissions, site partnerships, participant dosing, safety monitoring, and immunogenicity assessments.
Expertise Areas
- Vaccine design and development
- Protein nanoparticle platforms
- Antigen engineering and glycan modification
- Preclinical immunology and animal studies
Key Technologies
- Structure-guided antigen design
- Self-assembling protein nanoparticles
- Glycan trimming and glycoprotein engineering
- Recombinant protein expression